EGFR and non-small cell lung carcinoma: We have performed a phase II study to investigate the efficacy and safety of osimertinib in elderly Japanese patients (≥75 years old) with NSCLC containing the T790M mutation who progressed or experienced a relapse while receiving the first- and second- generations of EGFR-TKI treatment.